Jin Rong Jie·2025-04-21 11:56Company Overview - Junshi Biosciences closed at 29.46 yuan, up 2.65%, with a latest price-to-book ratio of 4.96 and a total market capitalization of 29.038 billion yuan [1] - As of February 28, 2025, Junshi Biosciences had 29,351 shareholders, an increase of 260 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - The main business of Junshi Biosciences includes the research and development of new drugs, technology transfer, and related services, as well as the production and sales of new drugs [1] - Key products include Toripalimab, Dihydrocodeine Bromide Tablets, Tifcemalimab, Adalimumab, Oncorhynchus mykiss monoclonal antibody, and various other monoclonal antibodies and inhibitors [1] - The company holds 175 authorized patents, with 129 domestic patents and 46 international patents, covering drug protein structures, preparation processes, uses, and formulation recipes, providing long-term patent protection for its products [1] Financial Performance - In the latest financial report for 2024, Junshi Biosciences achieved operating revenue of 1.948 billion yuan, a year-on-year increase of 29.67%, while net profit was -1.281 billion yuan, a year-on-year decrease of 43.90%, with a gross profit margin of 78.92% [1] Industry Comparison - Junshi Biosciences has a TTM PE ratio of -22.67 and a static PE ratio of -22.67, with a market capitalization of 29.038 billion yuan [2] - The industry average PE ratio is 44.27 (TTM) and 43.79 (static), with an average market capitalization of 18.383 billion yuan [2] - The industry median PE ratio is 38.38 (TTM) and 33.06 (static), with a median market capitalization of 7.437 billion yuan [2]